A Randomized, Multicenter, Open Label, Comparative Study to Evaluate the Immunogenicity and Reactogenicity of a Fully Liquid Pentavalent DTwP-HepB-Hib Vaccine (MyFiveTM, Panacea Biotec Ltd.) with Pentavalent DTwP-HepB/Hib Vaccine (Tritanrix-HBTM Reconstituted With HiberixTM, GSK) in Healthy Infants.

Trial Profile

A Randomized, Multicenter, Open Label, Comparative Study to Evaluate the Immunogenicity and Reactogenicity of a Fully Liquid Pentavalent DTwP-HepB-Hib Vaccine (MyFiveTM, Panacea Biotec Ltd.) with Pentavalent DTwP-HepB/Hib Vaccine (Tritanrix-HBTM Reconstituted With HiberixTM, GSK) in Healthy Infants.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Hib-DTP-hepatitis B vaccine (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 04 Jul 2012 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
    • 15 Feb 2012 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India.
    • 21 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top